Business Context and Reporting Period
This Form 8-K Current Report is filed by Globus Medical, Inc. on December 13, 2019. The report discloses corporate governance changes involving the resignation of a long-serving director and the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Director Resignation: Kurt C. Wheeler resigned from the Board of Directors on December 11, 2019, after 12 years of service. The resignation was not due to any disagreement regarding the Company's operations, policies, or practices.
- Director Appointment: Robert A. Douglas was appointed to the Board on December 11, 2019, to fill the vacancy. His term expires at the 2020 annual meeting.
- Committee Assignment: Mr. Douglas was appointed to the Audit Committee. The Board determined he qualifies as an "independent director" and an "audit committee financial expert."
Compensation and Governance Details
Mr. Douglas's compensation package includes:
- Annual Retainer: $57,500 for Board service.
- Committee Fee: $10,000 per year for Audit Committee service.
- Stock Option: An option to purchase up to 25,000 shares of Class A Common Stock at an exercise price of $56.89 (the closing price on December 11, 2019).
- Vesting Schedule: 25% vests on the first anniversary (December 11, 2020); the remaining balance vests ratably monthly over the subsequent 36 months.
- Indemnification: A standard indemnification agreement was executed.
Investor Verification Checklist
- Verify the independence status and financial expertise of the new director, Robert A. Douglas, as disclosed in the filing.
- Confirm the vesting schedule and exercise price of the stock options granted to Mr. Douglas to assess potential dilution.
- Review the press release (Exhibit 99.1) for any additional context regarding the Board composition changes.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial performance data.